secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2024-02-07T23:59:59+00:00
Accession:  0001171843-24-000648
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences: simufilam shows stable ADAS-Cog in mild Alzheimer's over 24 months
--------------------------------------------------------------------------------

- Mild Alzheimer's patients on continuous simufilam (n=47) averaged 0.07 point ADAS-Cog change (±1.51 SE) from baseline to month 24.
- Non-continuous mild group (n=40) declined 1.04 points on ADAS-Cog (±1.65 SE); largest separation during placebo withdrawal.
- Moderate Alzheimer's patients on continuous simufilam (n=32) declined 11.05 points on ADAS-Cog (±1.91 SE).
- Simufilam 100 mg twice daily safe and well tolerated; no drug-related serious adverse events; common TEAEs were COVID-19 and UTI.
- Phase 3 top-line results expected: 52-week study year-end 2024; 76-week study mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184324000648/0001171843-24-000648-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184324000648/f8k_020724.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-000648

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer